News Releases

Keyword Search

Oct-03-2022
Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma
Sep-27-2022
Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL
Sep-23-2022
Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
Sep-07-2022
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug-09-2022
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
Aug-02-2022
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results
Jul-14-2022
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL
Jun-10-2022
Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress
Jun-10-2022
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress
Jun-02-2022
Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022